USSTOCK.TODAY
Pre-Market
Log in Sign up

Novartis Discontinues Development of Cardiovascular Treatment Pelacarsen

Investing.com · ·by G4L

NVS Novartis AG ADR
$163.26 -0.26%
View chart & analysis →
  1. 1Novartis AG is halting the development of the injectable treatment pelacarsen.
  2. 2In clinical trials involving 8,322 patients over 7 years, the efficacy in preventing cardiovascular events was recorded at 0.
  3. 3Stephen Nissen stated that the clinical trial results were completely neutral, being neither harmful nor beneficial.

So what's the key point?

Novartis has decided to stop making the cardiovascular treatment pelacarsen. This is because tests on 8,322 people showed no effect in preventing the disease.

Source Investing.com · View original ↗

Related 3-line summaries

Illumina, Tempus AI, and Novartis Raise FY2026 Guidance Zacks · Nov 3Deutsche Bank Downgrades Novartis Rating and Adjusts Price Target Investing.com · Nov 2Swiss stocks outperform European markets as investors retreat from AI trades Investing.com · Oct 24
Today's 5 AI picks, all free
Nothing hidden: past picks and how they did against the S&P 500.
See today's picks →
← Back to news